U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C12H24O11
Molecular Weight 344.3129
Optical Activity UNSPECIFIED
Defined Stereocenters 9 / 9
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of LACTITOL

SMILES

C([C@@]([H])([C@]([H])([C@@]([H])([C@@]([H])(CO)O)O[C@@]1([H])[C@@]([H])([C@]([H])([C@]([H])([C@@]([H])(CO)O1)O)O)O)O)O)O

InChI

InChIKey=VQHSOMBJVWLPSR-JVCRWLNRSA-N
InChI=1S/C12H24O11/c13-1-4(16)7(18)11(5(17)2-14)23-12-10(21)9(20)8(19)6(3-15)22-12/h4-21H,1-3H2/t4-,5+,6+,7+,8-,9-,10+,11+,12-/m0/s1

HIDE SMILES / InChI

Description
Curator's Comment:: description was created based on several sources, including: https://health.mail.ru/drug/importal_n/ | http://www.druginfosys.com/drug.aspx?drugcode=2283&type=1 | https://medikamio.com/fr-ch/medicaments/importal-sachets-de-poudre-10-g/pil | http://www.tabletwise.com/medicine/lactitol-monohydrate

Lactitol is a sugar alcohol. This ingredient has been determined to be GRAS for specified uses as a direct food additive and foods containing lactitol are eligible for a health claim related to dental caries. Lactitol is used as an oral powder or solution in the management of hepatic encephalopathy and in case of short-term treatment of occasional constipation. Intestinal flora of large intestine is metabolize lactitol to low-molecular organic acid, which leads to an increase in osmotic pressure in intestine, increase in volume of fecal masses bowel function normalization. This drug might cause abdominal discomfort, especially flatulence and abdominal pain rarely or sometimes abdominal distension. These effects tend to diminish or disappear after a few days of regular intake of the drug. Since 'antacids and neomycin can neutralize ' acidifying effect of lactitol on stool, they should not be co-administered with lactitol in cirrhotic patients with hepatic encephalopathy; however both substances do not alter the 'laxative effect in patients with constipation.

Originator

Curator's Comment:: http://www.sugar-and-sweetener-guide.com/lactitol.html

Approval Year

Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Importal

Approved Use

It is recommended for the treatment of occasional constipation, stool regulation and chronic hepatic encephalopathy.
Primary
Importal

Approved Use

It is recommended for the treatment of occasional constipation, stool regulation and chronic hepatic encephalopathy.
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
776 ng/mL
20 g single, oral
dose: 20 g
route of administration: Oral
experiment type: SINGLE
co-administered:
LACTITOL serum
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: FED
2780 ng/mL
21 g single, oral
dose: 21 g
route of administration: Oral
experiment type: SINGLE
co-administered:
LACTITOL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: FASTED
776 ng/mL
21 g single, oral
dose: 21 g
route of administration: Oral
experiment type: SINGLE
co-administered:
LACTITOL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: HIGH-FAT
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
6.019 ng × h/mL
20 g single, oral
dose: 20 g
route of administration: Oral
experiment type: SINGLE
co-administered:
LACTITOL serum
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: FED
14941 ng × h/mL
21 g single, oral
dose: 21 g
route of administration: Oral
experiment type: SINGLE
co-administered:
LACTITOL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: FASTED
6019 ng × h/mL
21 g single, oral
dose: 21 g
route of administration: Oral
experiment type: SINGLE
co-administered:
LACTITOL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: HIGH-FAT
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
2.4 h
20 g single, oral
dose: 20 g
route of administration: Oral
experiment type: SINGLE
co-administered:
LACTITOL serum
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: FED
2.16 h
21 g single, oral
dose: 21 g
route of administration: Oral
experiment type: SINGLE
co-administered:
LACTITOL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: FASTED
2.43 h
21 g single, oral
dose: 21 g
route of administration: Oral
experiment type: SINGLE
co-administered:
LACTITOL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: HIGH-FAT
Doses

Doses

DosePopulationAdverse events​
20 g 1 times / day steady, oral
Recommended
Dose: 20 g, 1 times / day
Route: oral
Route: steady
Dose: 20 g, 1 times / day
Sources:
unhealthy, 18-87 years
n = 298
Health Status: unhealthy
Condition: chronic idiopathic constipation
Age Group: 18-87 years
Sex: M+F
Population Size: 298
Sources:
Other AEs: Urinary tract infection, Abdominal pain...
Other AEs:
Urinary tract infection (5%)
Abdominal pain (3%)
Hypersensitivity reaction
Rash
Pruritus
Sources:
20 g 1 times / day steady, oral
Recommended
Dose: 20 g, 1 times / day
Route: oral
Route: steady
Dose: 20 g, 1 times / day
Sources:
unhealthy, 18-88 years
n = 291
Health Status: unhealthy
Condition: chronic idiopathic constipation
Age Group: 18-88 years
Sex: M+F
Population Size: 291
Sources:
Disc. AE: Flatulence, Diarrhea...
Other AEs: Upper respiratory tract infection, Flatulence...
AEs leading to
discontinuation/dose reduction:
Flatulence (1%)
Diarrhea (1%)
Blood creatine phosphokinase increased (1%)
Increased blood pressure (1%)
Other AEs:
Upper respiratory tract infection (9%)
Flatulence (8%)
Diarrhea (4%)
Blood creatine phosphokinase increased (4%)
Abdominal distension (3%)
Increased blood pressure (3%)
Diarrhea (grade 3, 1%)
Sources:
130 g 1 times / day single, oral
Highest studied dose
Dose: 130 g, 1 times / day
Route: oral
Route: single
Dose: 130 g, 1 times / day
Sources:
healthy, 23-48 years
n = 21
Health Status: healthy
Age Group: 23-48 years
Sex: M+F
Population Size: 21
Sources:
74 g 1 times / day single, oral
MTD
Dose: 74 g, 1 times / day
Route: oral
Route: single
Dose: 74 g, 1 times / day
Sources:
healthy, 23-48 years
n = 21
Health Status: healthy
Age Group: 23-48 years
Sex: M+F
Population Size: 21
Sources:
DLT: Diarrhea, Gastrointestinal symptom NOS...
Dose limiting toxicities:
Diarrhea (15 patients)
Gastrointestinal symptom NOS (severe, 4 patients)
Sources:
AEs

AEs

AESignificanceDosePopulation
Hypersensitivity reaction
20 g 1 times / day steady, oral
Recommended
Dose: 20 g, 1 times / day
Route: oral
Route: steady
Dose: 20 g, 1 times / day
Sources:
unhealthy, 18-87 years
n = 298
Health Status: unhealthy
Condition: chronic idiopathic constipation
Age Group: 18-87 years
Sex: M+F
Population Size: 298
Sources:
Pruritus
20 g 1 times / day steady, oral
Recommended
Dose: 20 g, 1 times / day
Route: oral
Route: steady
Dose: 20 g, 1 times / day
Sources:
unhealthy, 18-87 years
n = 298
Health Status: unhealthy
Condition: chronic idiopathic constipation
Age Group: 18-87 years
Sex: M+F
Population Size: 298
Sources:
Rash
20 g 1 times / day steady, oral
Recommended
Dose: 20 g, 1 times / day
Route: oral
Route: steady
Dose: 20 g, 1 times / day
Sources:
unhealthy, 18-87 years
n = 298
Health Status: unhealthy
Condition: chronic idiopathic constipation
Age Group: 18-87 years
Sex: M+F
Population Size: 298
Sources:
Abdominal pain 3%
20 g 1 times / day steady, oral
Recommended
Dose: 20 g, 1 times / day
Route: oral
Route: steady
Dose: 20 g, 1 times / day
Sources:
unhealthy, 18-87 years
n = 298
Health Status: unhealthy
Condition: chronic idiopathic constipation
Age Group: 18-87 years
Sex: M+F
Population Size: 298
Sources:
Urinary tract infection 5%
20 g 1 times / day steady, oral
Recommended
Dose: 20 g, 1 times / day
Route: oral
Route: steady
Dose: 20 g, 1 times / day
Sources:
unhealthy, 18-87 years
n = 298
Health Status: unhealthy
Condition: chronic idiopathic constipation
Age Group: 18-87 years
Sex: M+F
Population Size: 298
Sources:
Blood creatine phosphokinase increased 1%
Disc. AE
20 g 1 times / day steady, oral
Recommended
Dose: 20 g, 1 times / day
Route: oral
Route: steady
Dose: 20 g, 1 times / day
Sources:
unhealthy, 18-88 years
n = 291
Health Status: unhealthy
Condition: chronic idiopathic constipation
Age Group: 18-88 years
Sex: M+F
Population Size: 291
Sources:
Diarrhea 1%
Disc. AE
20 g 1 times / day steady, oral
Recommended
Dose: 20 g, 1 times / day
Route: oral
Route: steady
Dose: 20 g, 1 times / day
Sources:
unhealthy, 18-88 years
n = 291
Health Status: unhealthy
Condition: chronic idiopathic constipation
Age Group: 18-88 years
Sex: M+F
Population Size: 291
Sources:
Flatulence 1%
Disc. AE
20 g 1 times / day steady, oral
Recommended
Dose: 20 g, 1 times / day
Route: oral
Route: steady
Dose: 20 g, 1 times / day
Sources:
unhealthy, 18-88 years
n = 291
Health Status: unhealthy
Condition: chronic idiopathic constipation
Age Group: 18-88 years
Sex: M+F
Population Size: 291
Sources:
Increased blood pressure 1%
Disc. AE
20 g 1 times / day steady, oral
Recommended
Dose: 20 g, 1 times / day
Route: oral
Route: steady
Dose: 20 g, 1 times / day
Sources:
unhealthy, 18-88 years
n = 291
Health Status: unhealthy
Condition: chronic idiopathic constipation
Age Group: 18-88 years
Sex: M+F
Population Size: 291
Sources:
Abdominal distension 3%
20 g 1 times / day steady, oral
Recommended
Dose: 20 g, 1 times / day
Route: oral
Route: steady
Dose: 20 g, 1 times / day
Sources:
unhealthy, 18-88 years
n = 291
Health Status: unhealthy
Condition: chronic idiopathic constipation
Age Group: 18-88 years
Sex: M+F
Population Size: 291
Sources:
Increased blood pressure 3%
20 g 1 times / day steady, oral
Recommended
Dose: 20 g, 1 times / day
Route: oral
Route: steady
Dose: 20 g, 1 times / day
Sources:
unhealthy, 18-88 years
n = 291
Health Status: unhealthy
Condition: chronic idiopathic constipation
Age Group: 18-88 years
Sex: M+F
Population Size: 291
Sources:
Blood creatine phosphokinase increased 4%
20 g 1 times / day steady, oral
Recommended
Dose: 20 g, 1 times / day
Route: oral
Route: steady
Dose: 20 g, 1 times / day
Sources:
unhealthy, 18-88 years
n = 291
Health Status: unhealthy
Condition: chronic idiopathic constipation
Age Group: 18-88 years
Sex: M+F
Population Size: 291
Sources:
Diarrhea 4%
20 g 1 times / day steady, oral
Recommended
Dose: 20 g, 1 times / day
Route: oral
Route: steady
Dose: 20 g, 1 times / day
Sources:
unhealthy, 18-88 years
n = 291
Health Status: unhealthy
Condition: chronic idiopathic constipation
Age Group: 18-88 years
Sex: M+F
Population Size: 291
Sources:
Flatulence 8%
20 g 1 times / day steady, oral
Recommended
Dose: 20 g, 1 times / day
Route: oral
Route: steady
Dose: 20 g, 1 times / day
Sources:
unhealthy, 18-88 years
n = 291
Health Status: unhealthy
Condition: chronic idiopathic constipation
Age Group: 18-88 years
Sex: M+F
Population Size: 291
Sources:
Upper respiratory tract infection 9%
20 g 1 times / day steady, oral
Recommended
Dose: 20 g, 1 times / day
Route: oral
Route: steady
Dose: 20 g, 1 times / day
Sources:
unhealthy, 18-88 years
n = 291
Health Status: unhealthy
Condition: chronic idiopathic constipation
Age Group: 18-88 years
Sex: M+F
Population Size: 291
Sources:
Diarrhea grade 3, 1%
20 g 1 times / day steady, oral
Recommended
Dose: 20 g, 1 times / day
Route: oral
Route: steady
Dose: 20 g, 1 times / day
Sources:
unhealthy, 18-88 years
n = 291
Health Status: unhealthy
Condition: chronic idiopathic constipation
Age Group: 18-88 years
Sex: M+F
Population Size: 291
Sources:
Diarrhea 15 patients
DLT, Disc. AE
74 g 1 times / day single, oral
MTD
Dose: 74 g, 1 times / day
Route: oral
Route: single
Dose: 74 g, 1 times / day
Sources:
healthy, 23-48 years
n = 21
Health Status: healthy
Age Group: 23-48 years
Sex: M+F
Population Size: 21
Sources:
Gastrointestinal symptom NOS severe, 4 patients
DLT, Disc. AE
74 g 1 times / day single, oral
MTD
Dose: 74 g, 1 times / day
Route: oral
Route: single
Dose: 74 g, 1 times / day
Sources:
healthy, 23-48 years
n = 21
Health Status: healthy
Age Group: 23-48 years
Sex: M+F
Population Size: 21
Sources:
PubMed

PubMed

TitleDatePubMed
Lactitol or lactulose in the treatment of chronic hepatic encephalopathy: results of a meta-analysis.
1992 Feb
Intestinal permeability in children: variation with age and reliability in the diagnosis of cow's milk allergy.
2001 May
Structural changes in natural actomyosin and surimi from ling cod (Ophiodon elongatus) during frozen storage in the absence or presence of cryoprotectants.
2001 Oct
Sugar alcohols enhance calcium transport from rat small and large intestine epithelium in vitro.
2002 Jun
Tributyrin and lactitol synergistically enhanced the trophic status of the intestinal mucosa and reduced histamine levels in the gut of nursery pigs.
2002 Mar
Health potential of polyols as sugar replacers, with emphasis on low glycaemic properties.
2003 Dec
Comparison of rifaximin and lactitol in the treatment of acute hepatic encephalopathy: results of a randomized, double-blind, double-dummy, controlled clinical trial.
2003 Jan
Effects of lactulose and lactitol on coliform bacteria and bacterial translocation in the caecum during 72-h starvation in rats.
2003 Jul
[Compressibility of directly compressed forms of lactitol].
2003 Sep
Nonabsorbable disaccharides for hepatic encephalopathy.
2004
Antagonistic activity of lactic acid bacteria as probiotics against selected bacteria of the Enterobaceriacae family in the presence of polyols and their galactosyl derivatives.
2004 Feb
Lactose derivatives are inhibitors of Trypanosoma cruzi trans-sialidase activity toward conventional substrates in vitro and in vivo.
2004 Jul
Oxalate degradation by intestinal lactic acid bacteria in dogs and cats.
2004 Jul 14
Constipation in adults.
2004 Jun
Combination of polydextrose and lactitol affects microbial ecosystem and immune responses in rat gastrointestinal tract.
2004 Jun
Effects of hyperosmolar agents--lactulose, lactitol, sodium phosphate and polyethylene glycol--on cecal coliform bacteria during traditional bowel cleansing: an experimental study in rats.
2004 May-Jun
Review: lactulose or lactitol may improve hepatic encephalopathy but may be less effective than antibiotics.
2004 Nov-Dec
[Nonabsorbable disaccharides for the treatment of hepatic encephalopathy--a systemic review of randomized clinical trials--a secondary publication].
2005 Jan 10
Comparison of rifaximin and lactulose for the treatment of hepatic encephalopathy: a prospective randomized study.
2005 Jun 30
[Pneumatosis intestinalis in 9 children with an oncologic disease].
2005 Mar 19
Pharmacological prophylaxis of hepatic encephalopathy after transjugular intrahepatic portosystemic shunt: a randomized controlled study.
2005 May
Short-chain fatty acid formation in the hindgut of rats fed oligosaccharides varying in monomeric composition, degree of polymerisation and solubility.
2005 Nov
Attenuated response of the serum triglyceride concentration to ingestion of a chocolate containing polydextrose and lactitol in place of sugar.
2005 Oct
[Intestinal function tests].
2005 Sep 14
Management of hepatic encephalopathy: focus on antibiotic therapy.
2006
Carbohydrate preference, acid tolerance and bile tolerance in five strains of Bifidobacterium.
2006 Apr
[The diagnostics and therapy of hepatic encephalopathy. Recommendations of of the working group on portal hypertension in the Czech Hepatology Society and the J. E. Purkinje Czech Medical Society].
2006 Jan
The trans-sialidase from Trypanosoma cruzi triggers apoptosis by target cell sialylation.
2006 Jul
Direct simultaneous determination of eight sweeteners in foods by capillary isotachophoresis.
2006 May
Prevention of first overt episode of hepatic encephalopathy after TIPS: no easy task.
2006 May
Molecular mobility and dynamic site heterogeneity in amorphous lactose and lactitol from erythrosin B phosphorescence.
2006 Sep 20
Characterization of the bga1-encoded glycoside hydrolase family 35 beta-galactosidase of Hypocrea jecorina with galacto-beta-D-galactanase activity.
2007 Apr
Constipation in adults.
2007 Aug 1
Anemia impairs small intestinal absorption measured by intestinal permeability in children.
2007 Jan
Effects of lactitol on intestinal microflora and plasma endotoxin in patients with chronic viral hepatitis.
2007 Jan
Accuracy of drug advertisements in medical journals under new law regulating the marketing of pharmaceutical products in Switzerland.
2008 Dec 31
Xylitol-supplemented nutrition enhances bacterial killing and prolongs survival of rats in experimental pneumococcal sepsis.
2008 Mar 11
Roles of probiotics and prebiotics in colon cancer prevention: Postulated mechanisms and in-vivo evidence.
2008 May
Treatment of minimal hepatic encephalopathy.
2008 Nov
[Prebiotic lactitol as a component of biopreparation from aerobic bacilli].
2008 Nov-Dec
Standards of medical care in diabetes--2009.
2009 Jan
Suppressive response of confections containing the extractive from leaves of Morus Alba on postprandial blood glucose and insulin in healthy human subjects.
2009 Jul 14
[Elderly hereditary hemorrhagic telangiectasia female with portosystemic encephalopathy].
2009 May
Freeze-drying of proteins with glass-forming oligosaccharide-derived sugar alcohols.
2010 Apr 15
Successful drug development despite adverse preclinical findings part 2: examples.
2010 Dec
Microbial and bioconversion production of D-xylitol and its detection and application.
2010 Dec 15
Standards of medical care in diabetes--2010.
2010 Jan
Constipation in adults.
2010 Jul 5
Pharmacotherapy for hepatic encephalopathy.
2010 Jun 18
Recombinant human granulocyte colony stimulating factor pre-screening and screening of stabilizing carbohydrates and polyols.
2010 Mar 15
Patents

Sample Use Guides

Initial dose - 20 g at once during 4-5 days. Next, 10 g per day.
Route of Administration: Oral
The species of bifidobacteria, which were detected in vessel of each fermentation after adaptation to an Lactitol 1% (wt/vol): Bifidobacterium adolescentis, B. bifidum, B. longum, B. dentium and B. catenulatum. B. angulatum, B. breve and B. infantis were not detected.
Name Type Language
LACTITOL
INCI   INN   MI   WHO-DD  
INN   INCI  
Official Name English
LACTITOL ANHYDROUS
Common Name English
LACTOBIOSIT
Common Name English
MIRUHEN
Common Name English
LACTITOL ACM 50
Common Name English
NSC-231323
Code English
E-966
Code English
IMPORTAL
Brand Name English
4-O-.BETA.-D-GALACTOPYRANOSYL-D-GLUCITOL
Common Name English
LACTITOL [USP-RS]
Common Name English
LACTY (SACCHARIDE)
Common Name English
INS-966
Code English
D-LACTITOL
Common Name English
MILCHEN
Common Name English
LACTITOL [MI]
Common Name English
LACTITOL [WHO-DD]
Common Name English
LACTOSITOL
Common Name English
LACTITOL [INN]
Common Name English
FINLAC DC
Common Name English
LACTOSIT
Common Name English
INS NO.966
Code English
LACTITOL [INCI]
Common Name English
Classification Tree Code System Code
WHO-VATC QA06AD12
Created by admin on Sat Jun 26 01:26:32 UTC 2021 , Edited by admin on Sat Jun 26 01:26:32 UTC 2021
JECFA EVALUATION INS-966
Created by admin on Sat Jun 26 01:26:32 UTC 2021 , Edited by admin on Sat Jun 26 01:26:32 UTC 2021
WHO-ATC A06AD12
Created by admin on Sat Jun 26 01:26:32 UTC 2021 , Edited by admin on Sat Jun 26 01:26:32 UTC 2021
NCI_THESAURUS C283
Created by admin on Sat Jun 26 01:26:32 UTC 2021 , Edited by admin on Sat Jun 26 01:26:32 UTC 2021
CODEX ALIMENTARIUS (GSFA) INS-966
Created by admin on Sat Jun 26 01:26:32 UTC 2021 , Edited by admin on Sat Jun 26 01:26:32 UTC 2021
DSLD 1130 (Number of products:1)
Created by admin on Sat Jun 26 01:26:32 UTC 2021 , Edited by admin on Sat Jun 26 01:26:32 UTC 2021
Code System Code Type Description
MERCK INDEX
M6659
Created by admin on Sat Jun 26 01:26:32 UTC 2021 , Edited by admin on Sat Jun 26 01:26:32 UTC 2021
PRIMARY Merck Index
ChEMBL
CHEMBL296306
Created by admin on Sat Jun 26 01:26:32 UTC 2021 , Edited by admin on Sat Jun 26 01:26:32 UTC 2021
PRIMARY
EVMPD
SUB126857
Created by admin on Sat Jun 26 01:26:32 UTC 2021 , Edited by admin on Sat Jun 26 01:26:32 UTC 2021
PRIMARY
HSDB
7970
Created by admin on Sat Jun 26 01:26:32 UTC 2021 , Edited by admin on Sat Jun 26 01:26:32 UTC 2021
PRIMARY
EU FOOD ADDITIVES
E 966
Created by admin on Sat Jun 26 01:26:32 UTC 2021 , Edited by admin on Sat Jun 26 01:26:32 UTC 2021
PRIMARY
CAS
585-86-4
Created by admin on Sat Jun 26 01:26:32 UTC 2021 , Edited by admin on Sat Jun 26 01:26:32 UTC 2021
PRIMARY
WIKIPEDIA
LACTITOL
Created by admin on Sat Jun 26 01:26:32 UTC 2021 , Edited by admin on Sat Jun 26 01:26:32 UTC 2021
PRIMARY
MESH
C014635
Created by admin on Sat Jun 26 01:26:32 UTC 2021 , Edited by admin on Sat Jun 26 01:26:32 UTC 2021
PRIMARY
EPA CompTox
585-86-4
Created by admin on Sat Jun 26 01:26:32 UTC 2021 , Edited by admin on Sat Jun 26 01:26:32 UTC 2021
PRIMARY
USP_CATALOG
1356687
Created by admin on Sat Jun 26 01:26:32 UTC 2021 , Edited by admin on Sat Jun 26 01:26:32 UTC 2021
PRIMARY USP-RS
PUBCHEM
157355
Created by admin on Sat Jun 26 01:26:32 UTC 2021 , Edited by admin on Sat Jun 26 01:26:32 UTC 2021
PRIMARY
EVMPD
SUB08385MIG
Created by admin on Sat Jun 26 01:26:32 UTC 2021 , Edited by admin on Sat Jun 26 01:26:32 UTC 2021
PRIMARY
ECHA (EC/EINECS)
209-566-5
Created by admin on Sat Jun 26 01:26:32 UTC 2021 , Edited by admin on Sat Jun 26 01:26:32 UTC 2021
PRIMARY
DRUG BANK
DB12942
Created by admin on Sat Jun 26 01:26:32 UTC 2021 , Edited by admin on Sat Jun 26 01:26:32 UTC 2021
PRIMARY
RXCUI
28395
Created by admin on Sat Jun 26 01:26:32 UTC 2021 , Edited by admin on Sat Jun 26 01:26:32 UTC 2021
PRIMARY RxNorm
JECFA MONOGRAPH
INS-966
Created by admin on Sat Jun 26 01:26:32 UTC 2021 , Edited by admin on Sat Jun 26 01:26:32 UTC 2021
PRIMARY
FDA UNII
L2B0WJF7ZY
Created by admin on Sat Jun 26 01:26:32 UTC 2021 , Edited by admin on Sat Jun 26 01:26:32 UTC 2021
PRIMARY
INN
6414
Created by admin on Sat Jun 26 01:26:32 UTC 2021 , Edited by admin on Sat Jun 26 01:26:32 UTC 2021
PRIMARY
DRUG CENTRAL
1534
Created by admin on Sat Jun 26 01:26:32 UTC 2021 , Edited by admin on Sat Jun 26 01:26:32 UTC 2021
PRIMARY
NCI_THESAURUS
C81025
Created by admin on Sat Jun 26 01:26:32 UTC 2021 , Edited by admin on Sat Jun 26 01:26:32 UTC 2021
PRIMARY